featured-image

, /PRNewswire/ -- Immunocan announced the successful construction of new strain of fully human antibody platform: ImmuMab® HKL mouse. This new mouse was created by in-situ replacing the variable region of Immunoglobulin genes of mouse by its counterparts from human. With Lambda light chain genes humanized, ImmuMab® HKL mouse now contains approximately 3.

2 Mb of human immunoglobulin variable region genes, making it the humanized mouse with the longest human immunoglobulin variable regions in the world. Since the first mouse-derived monoclonal antibody drug OKT3 (muromonab-CD3) was marketed in 1986, over 120 antibody drugs from different sources have been approved by FDA and brought clinical benefits to patients. Despite flexibility and well-established application process, ritual use of mice during antibody generation brought limitations for drug development space.



Due to the low utilization of Immunoglobulin Lambda genes in wildtype mice (about 5%, varying by strain), antibodies with Lambda light chain (λ-antibodies) have always been under-scrutinized. As of , only 14 FDA-approved antibody drugs contain Lambda light chain, and most of these are from transgenic mice or human antibody library used in display technologies. In humans, naturally occurring λ-antibodies are approximately 35% of the antibody repertoire and plays important role in adaptive immunity.

Different individuals generate immune repertoires with different preferences of light chain type in response to diff.

Back to Health Page